Sleep Optimization. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first isolated from rabbit brain tissue in 197...
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first isolated from rabbit brain tissue in 1977. It was named for its ability to induce delta wave (deep) sleep in animal models. DSIP has been studied for its effects on sleep architecture, stress response, and neuroendocrine regulation.
DSIP's mechanism remains partially understood. It appears to modulate sleep by influencing GABAergic and glutamatergic signaling, and may act on the hypothalamic sleep-wake regulatory centers. Research suggests it normalizes disrupted sleep patterns rather than sedating — a distinction from conventional sleep medications. It also appears to modulate cortisol and ACTH levels.
Important: The evidence base for DSIP varies by application. Many findings are from preclinical (animal or in vitro) studies. Large-scale human clinical trials may not be completed. Always evaluate the quality of evidence before drawing conclusions.
Generally well-tolerated in limited clinical studies. Reported effects include morning grogginess at higher doses and mild headache. The limited scope of clinical data means the full safety profile is not established.
DSIP is not FDA-approved and is not on the Category 1 or Category 2 lists. It is available as a research chemical for laboratory use.
These verified suppliers carry DSIP with third-party COAs and US-based shipping.